Industry Satellite Symposia
Thursday 4 June 2026 08:00–08:45 WEST Auditorium III+IV Centro de Congressos de Lisboa, | Converging paths in bronchiectasis: shared therapeutic strategies for a heterogeneous disease Boehringer Ingelheim satellite symposium at ECFS 2026 |
|---|
| Co-chairs: Marcus Mall, Berlin, DE and Eva Polverino, Barcelona, ES | ||
| Time (WEST) | Presentation title | Presenter |
| 08:00–08:03 | Welcome and introduction 3min | Marcus Mall |
| 08:03–08:23 | Presentation and Discussion Intersections in the management of CF and non-CF bronchiectasis 10 min presentation; 10 min discussion/Q&A | Marcus Mall |
| 08:23–08:43 | Presentation and Discussion A new direction: how do DPP1 inhibitors fit into the treatment landscape? 10 min presentation; 10 min discussion/Q&A | Eva Polverino |
| 08:43–08:45 | Final remarks and meeting close 2 min | Eva Polverino |
This promotional symposium is organised and funded entirely by Vertex Pharmaceuticals (Europe) Limited.
Due to pharmaceutical industry regulations, this symposium is for healthcare professionals and scientific professionals only. It is not open to patients or members of the public.
ALYFTREK®▼ (deutivacaftor/tezacaftor/vanzacaftor) Prescribing Information and adverse event reporting information can be found below and will be available at the meeting.
Thursday 4 June 2026 13:00–14:00 WEST Auditório I, | Reaching new heights in CF Care |
|---|
Objectives:
| ||
| Time (WEST) | Presentation | Speaker |
13:00–13:05 | Welcome and opening | Prof Dr Carsten Schwarz |
13:05–13:20 | ALYFTREK® (deutivacaftor/tezacaftor/vanzacaftor): Latest data for the next-generation CFTRm | Prof Dr Carsten Schwarz |
13:20–13:50 | ALYFTREK® in clinical practice: Real-world adult and paediatric experience | Dr Tavs Qvist and Prof Paul McNally |
13:50–14:00 | Q&A and close | All, facilitated by |
Questions and comments from the audience are encouraged throughout the symposium.
CLICK HERE for ALYFTREK® (deutivacaftor/tezacaftor/vanzacaftor) Portuguese SmPC
Healthcare professionals are asked to report any suspected adverse reactions.
Adverse events should be reported to Vertex Pharmaceuticals (Europe) Limited at vertexmedicalinfo@vrtx.com.
▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information.
Medicamento sujeito a receita médica restrita – alínea a) do artigo 118 do DL 176/2006, na sua redação atual. Alyftrek 50 mg + 20 mg + 4 mg e Alyftrek 125 mg + 50 mg + 10 mg comprimidos não são comparticipados. Para mais informações deverá contactar o titular da AIM ou o representante local: Vertex Pharmaceuticals (Portugal), Unipessoal Lda., Rua Tomás da Fonseca, Centro Empresarial Torres de Lisboa, Torre G, 2º piso, 1600-209 Lisboa, NIPC: 513481613.
Abbreviations:
CF, cystic fibrosis; CFTRm, cystic fibrosis transmembrane conductance regulator modulator; Q&A, question and answer; SmPC, Summary of Product Characteristics; WEST, Western European Summer Time.
DM-34-2600012 | April 2026
Thursday 4 June 2026 19:00–20:30 WEST Sala 3A | Sionna Networking Reception (by invitation only) | |
|---|---|---|
This symposium is organised and funded entirely by Vertex Pharmaceuticals (Europe) Limited.
Due to pharmaceutical industry regulations, this symposium is for healthcare professionals and scientific professionals only. It is not open to patients or members of the public.
Friday 5 June 2026 13:00–14:00 WEST Auditório I, | shaping the future of CF Care | |
|---|---|---|
Objectives:
| ||
| Time (WEST) | Presentation | |
13:00–13:10 | Opening Session | |
13:10–13:45 | Disease progression in the era of CFTRm – still a cause for concern? | |
13:45–13:50 | The continued progress in providing treatment to potentially all pwCF | |
13:50–14:00 | Q&A and closing summary | |
Questions and comments from the audience are encouraged throughout the symposium.
Abbreviations:
CF, cystic fibrosis; CFTR, cystic fibrosis transmembrane conductance regulator; CFTRm, CFTR modulator; pwCF, people with cystic fibrosis; Q&A, question and answer; WEST, Western European Summer Time.
AC-20-2600016 | March 2026